TrialBritish journal of cancer1997

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.

M Ando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.